Formulation Development White Papers & Articles
-
Following The Science To Develop Best-In-Class Cancer Drugs
12/11/2023
As innovative cancer therapeutics continue to enter the clinical trial pipeline, some developers are shifting their focus towards developing drugs that are safe and efficacious with minimal toxicity.
-
A Lean, Agile Business Model To Deliver High-Quality Oncologic Treatments
12/11/2023
No two journeys through the drug pipeline are the same; the ability to leverage a variety of approaches for different products is what sets one lean biotech company apart.
-
A Tale Of Two Brothers: The Abpro Founders
12/11/2023
By founding their latest venture, Abpro, Ian and Eugene Chan are using their synergistic skillsets in business and medicine to rapidly generate antibodies that treat cancer and autoimmune diseases.
-
Early Development Considerations For Late-Stage NCE Success – Part One
12/8/2023
Navigating NCE development can be daunting. Learn about the importance of assessing and mitigating risk at every stage of development and ensure that your NCE has the maximum potential for success.
-
What Information Does A CDMO Need To Deliver A Good Proposal?
12/6/2023
Learn about the importance of sharing as much information as possible with your CDMO and how asking the right set of questions will ensure that services are fairly priced and timelines are accurate.
-
Welcoming The “Era Of ADCs”
12/5/2023
Dr. Loretta Itri sat down to explore the promise of TRODELVY®️ and other antibody-drug conjugates as transformative treatments for a range of malignancies and intractable diseases.
-
Genome Editing Using mRNA-Lipid Nanoparticles For CAR T Cell Therapy
11/22/2023
Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.
-
Increasing Bioavailability With Amorphous Solid Dosage Formulations
11/10/2023
Discover the challenges associated with pH-dependent solubility for oral tyrosine kinase inhibitor drugs and how leveraging ASD formulation can help create more effective, patient-friendly drug products.
-
Nitrosamine Impurities Deadline: Are Your Products Compliant?
11/6/2023
The FDA nitrosamine contamination guidance set deadlines of Nov. 1, 2023, for risk assessment updates and Aug. 1, 2025, for full NDSRI limit compliance.
-
The Future Of ADC Manufacturing
11/2/2023
Enhance your ADC manufacturing processes by leveraging the performances and inherent benefits of single-use isolators.